For example, aromatase inhibitors, a major first line endocrine therapy for postmenopausal metastatic ER+ breast cancer that operate via inhibiting estradiol synthesis rather than by inhibiting ERα66 (85,86) may not follow the mechanisms of reversible drug resistance as proposed here. This evidence concerns the gene CYP19A1 and breast cancer.